• Skip to main content
  • Skip to primary sidebar

Tracking Health and Wellness Applications of Brain Science

Spanish
sb-logo-with-brain
  • Resources
    • Monthly eNewsletter
    • Solving the Brain Fitness Puzzle
    • The SharpBrains Guide to Brain Fitness
    • How to evaluate brain training claims
    • Resources at a Glance
  • Brain Teasers
    • Top 25 Brain Teasers & Games for Teens and Adults
    • Brain Teasers for each Cognitive Ability
    • More Mind Teasers & Games for Adults of any Age
  • Virtual Summits
    • 2019 SharpBrains Virtual Summit
    • Speaker Roster
    • Brainnovations Pitch Contest
    • 2017 SharpBrains Virtual Summit
    • 2016 SharpBrains Virtual Summit
    • 2015 SharpBrains Virtual Summit
    • 2014 SharpBrains Virtual Summit
  • Report: Pervasive Neurotechnology
  • Report: Digital Brain Health
  • About
    • Mission & Team
    • Endorsements
    • Public Speaking
    • In the News
    • Contact Us

cognitive-health

Without Brain Health, you do not have Health

February 10, 2023 by Dr. Sandra Bond Chapman

As you go through life, your brain under­goes extra­or­di­nary devel­op­ment. Your brain is the most adapt­able, mod­i­fi­able organ in your body, and it can change both pos­i­tive­ly and neg­a­tive­ly by how you use it each day. Just by read­ing a book such as this one, your brain has been changed.

How has your brain been altered through­out your life? How may it change in years and decades ahead? The good news is that much of the age-relat­ed decline is like­ly avoid­able and even reversible. The fact that you bought and have read this book to the very end tells me you are moti­vat­ed to do some­thing about your brain per­for­mance. Our cog­ni­tive brain health tends to decline over time because we let it, but you can be your own brain health fit­ness coach to max­i­mize brain func­tion. Grow­ing brain research shows that a major­i­ty of indi­vid­u­als can make their brain smarter every sin­gle day. [Read more…] about With­out Brain Health, you do not have Health

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Education & Lifelong Learning Tagged With: brain, brain disease, brain health, brain span, Brain-Fitness, brain-injury, brain-performance, Brain-Scientist, cognitive brain health, cognitive potential, cognitive scientist, cognitive-health, health, Innovations, intellectual capital, optimize brain health

Building cognitive reserve helps delay memory and thinking decline regardless of genetic or childhood markers

August 30, 2022 by SharpBrains

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing time­ly brain news and a few fun brain teasers to test your per­cep­tu­al and cog­ni­tive skills.

#1. Study: Build­ing cog­ni­tive reserve helps delay mem­o­ry and think­ing decline regard­less of genet­ic or child­hood markers

“While our child­hood can influ­ence our mem­o­ry and think­ing skills lat­er in life, this research under­lines the mes­sage that it’s nev­er too late to take action to sup­port cog­ni­tive health.” — Dr Sara Imari­sio, Head of Strate­gic Ini­tia­tives at Alzheimer’s Research UK

#2. Ful­ly-auto­mat­ed analy­sis of voice recordings–from neu­ropsy­cho­log­i­cal tests–found to help dif­fer­en­ti­ate nor­mal cog­ni­tion from demen­tia and mild cog­ni­tive impairment

As the researchers point out, “The pro­posed approach offers a ful­ly auto­mat­ed iden­ti­fi­ca­tion of MCI and demen­tia based on a record­ed neu­ropsy­cho­log­i­cal test, pro­vid­ing an oppor­tu­ni­ty to devel­op a remote screen­ing tool that could be adapt­ed eas­i­ly to any language”

#3. Debunk­ing the “chem­i­cal imbal­ance” the­o­ry yet not throw­ing out the anti­de­pres­sant baby with the bathwater

“Depres­sion is usu­al­ly man­aged effec­tive­ly with anti­de­pres­sants or by talk­ing treat­ments, such as cog­ni­tive behav­iour ther­a­py, despite an incom­plete under­stand­ing of the con­di­tion and how these treat­ments work. We can­not know if treat­ments address the under­ly­ing prob­lem because we haven’t yet iden­ti­fied what that is. To imply that SSRI anti­de­pres­sants may not be worth­while is to mis­un­der­stand an evi­dence base that says the very opposite.”

#4. Q&A with researcher Robb Rut­ledge on men­tal health, expec­ta­tions, deci­sion-mak­ing and hol­i­day planning

“Recent events have a big­ger impact on hap­pi­ness than ear­li­er events, so it can be a good strat­e­gy to save a cou­ple things that have a chance of a big pos­i­tive sur­prise for the last few days of your trip. It could be a nov­el expe­ri­ence that a lot of peo­ple like but you’re not sure what to expect … It prob­a­bly isn’t anoth­er muse­um. Just make sure it’s not some­thing that could get rained out”

#5. How much should you trust Bet­ter­Help, Talk­space, Cere­bral and oth­er men­tal health start-ups tout­ed by celebrities?

“Many U.S. adults aren’t able to find help because of a short­age of ther­a­pists. Near­ly 40% are strug­gling with men­tal health or sub­stance abuse issues, accord­ing to the Cen­ters for Dis­ease Con­trol and Prevention.
So mil­lions of peo­ple are turn­ing to online companies…”

#6. Dig­i­tal men­tal health inter­ven­tion by the World Health Orga­ni­za­tion (WHO) found to low­er anx­i­ety and depres­sion, with improve­ments main­tained at 3?month follow-up

As acknowl­edged “The main lim­i­ta­tion of the cur­rent tri­al is the high dropout rate”, but con­text is key: “Most dis­placed peo­ple with men­tal dis­or­ders in low- and mid­dle-income coun­tries do not receive effec­tive care, and their access to care has dete­ri­o­rat­ed dur­ing the Coro­n­avirus Dis­ease 2019 (COVID-19) pan­dem­ic”. — Inno­va­tion does­n’t need to be per­fect, just better/ cheaper/ more acces­si­ble than alternatives.

#7. Dig­i­tal ther­a­peu­tics pio­neer Akili Inter­ac­tive Labs goes pub­lic, rais­ing $150M+; trades down 49% first day

Quite dif­fi­cult mar­ket envi­ron­ment for an impor­tant evi­dence-based inno­va­tion — good news is they raised enough funds to test approach in the real world over the next 12–24 months. Let’s see!

#8. Arti­fi­cial Intel­li­gence (AI) meets Cog­ni­tive Behav­ioral Ther­a­py (CBT): Wysa rais­es $20M to scale up men­tal health chatbot

“Typ­i­cal­ly, access to a men­tal health ser­vice is gat­ed. It is restrict­ed by some kind of diag­no­sis — say­ing only if you are severe enough you will be able to get to speak to a ther­a­pist because obvi­ous­ly ther­a­py is expen­sive and somebody’s got to pay for it” … the app offers “ear­ly engage­ment and a safe space where peo­ple can come in and anony­mous­ly just talk about what’s both­er­ing them.”

Final­ly, here are three quick brain teas­er games to test your per­cep­tu­al and cog­ni­tive skills. Wish­ing you and yours a healthy and stim­u­lat­ing month of September!

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain Teasers, Brain/ Mental Health, Education & Lifelong Learning, SharpBrains Monthly eNewsletter, Technology & Innovation Tagged With: Akili Interactive Labs, antidepressants, cognitive behaviour therapy, cognitive-health, cognitive-reserve, dementia, digital mental health, digital therapeutics, mild-cognitive-impairment, neuropsychological-tests, normal cognition

A conversation at the frontier of digital health innovation, FDA regulations, and cognitive health

March 23, 2022 by SharpBrains

Dig­i­tal Ther­a­peu­tics for MCI and Alzheimer’s dis­ease: A Reg­u­la­to­ry Per­spec­tive (The Jour­nal of Pre­ven­tion of Alzheimer’s Disease):

–This arti­cle is adapt­ed from a com­pre­hen­sive con­ver­sa­tion between Dr. Murali Doraiswamy and Dr. Jef­frey Shuren at the 2021 Clin­i­cal Tri­als on Alzheimer’s Dis­ease (CTAD) con­fer­ence in Boston. Dr. Shuren is a behav­ioral neu­rol­o­gist who has held a vari­ety of lead­er­ship roles at the FDA and CMS, includ­ing as Direc­tor of the Cen­ter for Devices and Radi­o­log­i­cal Health (CDRH).

MD: The CDRH has a flag­ship Dig­i­tal Health Cen­ter of Excel­lence. Can you tell us about it? And can you share your advice for how the Alzheimer’s field can help spur dig­i­tal inno­va­tion? [Read more…] about A con­ver­sa­tion at the fron­tier of dig­i­tal health inno­va­tion, FDA reg­u­la­tions, and cog­ni­tive health

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Technology & Innovation Tagged With: Alzheimer’s Disease, CDRH, cognitive-health, CTAD, digital health, Digital Health Center of Excellence, digital health innovation, Dr. Jeffrey Shuren, Dr. Murali Doraiswamy, FDA, innovation, MCI, precertification

Update on the aducanumab (Aduhelm) saga, retirement, financial advice, cognitive health, excessive worrying, neurotech, and more

June 30, 2021 by SharpBrains

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, pro­vid­ing this time a sum­ma­ry of the saga around the FDA approval of adu­canum­ab (Aduhelm) as a sup­posed treat­ment for Alzheimer’s Dis­ease, plus a range of time­ly research find­ings and resources for life­long brain health.

First, below are some key reads to nav­i­gate “prob­a­bly the worst drug approval deci­sion in recent U.S. his­to­ry” — Dr. Aaron Kessel­heim, the Pro­fes­sor of Med­i­cine at Har­vard Med­ical School who resigned rom the FDA Advi­so­ry Com­mit­tee in protest.

#1. Grow­ing back­lash against the FDA approval of unproven Alzheimer’s treat­ment Aduhelm, by Bio­gen:

“The Insti­tute for Clin­i­cal and Eco­nom­ic Review (ICER) believes that the FDA, in approv­ing adu­canum­ab (Aduhelm by Bio­gen) for the treat­ment of Alzheimer’s dis­ease, has failed in its respon­si­bil­i­ty to pro­tect patients and fam­i­lies from unproven treat­ments with known harms.”

#2. First, do no harm? Six rea­sons to approach anti-amy­loid drug Aduhelm cau­tious­ly, if at all:

“The FDA’s approval of Aduhelm rais­es more ques­tions and cre­ates more prob­lems than a new drug approval should. It’s time for gov­ern­men­tal, pro­fes­sion­al, and advo­ca­cy enti­ties to step in where Bio­gen and the FDA have failed and explain to patients, care­givers, and clin­i­cians how this drug is not the “new day” in the fight against Alzheimer’s dis­ease and needs to be approached cau­tious­ly, if at all.” — Dr. Sam Gandy, Pro­fes­sor of Neu­rol­o­gy and Psy­chi­a­try at the Icahn School of Med­i­cine at Mount Sinai, where he holds the Mount Sinai Chair in Alzheimer’s Research

#3. Can the con­tro­ver­sial FDA approval of Aduhelm back­fire and delay the dis­cov­ery of actu­al Alzheimer’s treat­ments? (Yes, it can):

“In short, while the amy­loid hypoth­e­sis has fal­tered, the approval of adu­canum­ab, which is based pri­mar­i­ly on this the­o­ry, sug­gests that the the­o­ry may once again dom­i­nate research, and could reduce the chances of find­ing more promis­ing treat­ments. For exam­ple, tau pro­tein, which also accu­mu­lates in the brains of Alzheimer’s patients — long before the amy­loid pro­tein does — has been shown to be close­ly asso­ci­at­ed with the cog­ni­tive impair­ment result­ing from the dis­ease … we must not inter­rupt research on bio­mark­ers and new ther­a­peu­tic approaches.”

#4. US Sen­a­tor Joe Manchin calls for a new FDA Com­mis­sion­er to replace cur­rent (act­ing) one who “has repeat­ed­ly ignored pub­lic health con­cerns and shown a dere­lic­tion of duty” over opi­oids and adu­canum­ab:

“I write today con­cern­ing the lack of per­ma­nent lead­er­ship at the Food and Drug Admin­is­tra­tion (FDA), and the con­tin­ued tenure of Dr. Janet Wood­cock as inter­im com­mis­sion­er. Just last week, the FDA grant­ed approval for Aduhelm (adu­canum­ab), a treat­ment for Alzheimer’s, despite its advi­so­ry pan­el vot­ing near­ly unan­i­mous­ly against its approval, with no pan­el mem­ber vot­ing in favor of approval”

(Let’s hope some­thing use­ful emerges from this very unhealthy FDA deci­sion. Quite dis­turb­ing, though, to notice the links between the opi­oid epi­dem­ic and the recent Aduhelm approval.)

#5. Health payers–including Medicare and Point32Health–to ques­tion Aduhelm pric­ing and its “rea­son­able and nec­es­sary” use:

“Under the broad label that FDA approved, the drug is avail­able to all Alzheimer’s patients, and the agency did not place lim­its on treat­ment dura­tion sug­gest­ing that patients could remain on the drug indef­i­nite­ly. We are trou­bled by reports that those fac­tors could lead the drug to com­mand “some­where between” the $37 bil­lion we cur­rent­ly spend on Medicare Part B and the $90 bil­lion we cur­rent­ly spend on Medicare Part D. This lev­el of poten­tial new spend­ing, par­tic­u­lar­ly for just one prod­uct with lim­it­ed evi­dence of clin­i­cal effi­ca­cy thus far, tests the program’s resiliency.”

The stakes could­n’t be higher.

Now let’s review oth­er impor­tant devel­op­ments in June.

#6. Debate: What is the role of finan­cial advi­sors and plat­forms in detect­ing and address­ing cog­ni­tive decline among old­er clients?:

” … big do-it-your­self invest­ing and trad­ing venues like Van­guard Group, Fideli­ty Invest­ments and Charles Schwab Corp. are strength­en­ing some of the ways they detect pos­si­ble signs of decline. Among oth­er things, all three firms check for clients’ dif­fi­cul­ty nav­i­gat­ing secu­ri­ty pro­to­cols or need for fre­quent pass­word resets. In such cas­es, a des­ig­nat­ed fam­i­ly mem­ber might be informed.

Van­guard also checks client-call record­ings for keywords—such as “con­fused” and “dementia”—that might sig­nal trouble.”

#7. Study in Chi­na finds that retire­ment may accel­er­ate cog­ni­tive decline, even for those with sta­ble income:

“While retire­ment schemes like the 401(k) and sim­i­lar pro­grams in oth­er coun­tries are typ­i­cal­ly intro­duced to ensure the wel­fare of aging adults, our research sug­gests they need to be designed care­ful­ly to avoid unin­tend­ed and sig­nif­i­cant adverse con­se­quences. When peo­ple con­sid­er retire­ment, they should weigh the ben­e­fits with the sig­nif­i­cant down­sides of a sud­den lack of men­tal activ­i­ty. A good way to ame­lio­rate these effects is to stay engaged in social activ­i­ties and con­tin­ue to use your brains in the same way you did when you were working.

In short, we show that if you rest, you rust.”

#8. The explo­sion of men­tal health apps rais­es sub­stan­tial opportunities–and tough ques­tions:

“Dig­i­tal men­tal health can be viewed as a way to extend the men­tal resources that we have,” said David Mohr, who directs the Cen­ter for Behav­ioral Inter­ven­tion Tech­nolo­gies at the North­west­ern Uni­ver­si­ty Fein­berg School of Med­i­cine. A step-care mod­el, for exam­ple, would allow patients with milder symp­toms to be treat­ed via tech­nol­o­gy while reserv­ing in-per­son care for patients who need some­thing more.

#9. Pre­scrip­tion soft­ware firm Pear Ther­a­peu­tics to go pub­lic via $1.6 bil­lion SPAC deal, har­ness­ing 3 FDA-autho­rized prod­ucts and 14 can­di­dates:

“Pear is one of nine com­pa­nies invit­ed to par­tic­i­pate in the U.S. Food and Drug Administration’s (FDA) Pre­cer­ti­fi­ca­tion Pilot Pro­gram. Pear has devel­oped and com­mer­cial­ized the first three FDA-autho­rized PDTs, has 14 prod­uct can­di­dates, and is scal­ing its plat­form for third-par­ty prod­uct dis­tri­b­u­tion oppor­tu­ni­ties. The Company’s three FDA-autho­rized prod­ucts, reSET®, reSET‑O® and Som­ryst®, address large mar­ket oppor­tu­ni­ties with more than 20 mil­lion patients suf­fer­ing from sub­stance and opi­oid use dis­or­ders and more than 30 mil­lion from chron­ic insom­nia, in the U.S. alone, respectively.”

#10. Don’t wor­ry, be hap­py: How exces­sive wor­ry­ing may influ­ence the rate of neu­rode­gen­er­a­tion:

“(Research find­ings) sug­gest that cog­ni­tive func­tion may need to be mon­i­tored close­ly in indi­vid­u­als with affec­tive dis­or­ders, as these indi­vid­u­als may be at par­tic­u­lar risk of greater cog­ni­tive decline.”

#11. Smarter cars are com­ing soon … : Eye-track­ing pio­neer Smart Eye acquires MIT spin-off Affec­ti­va to aug­ment dri­ver mon­i­tor­ing sys­tems and more

#12. And, much more: DARPA-fund­ed non­sur­gi­cal neu­rotech­nolo­gies push the fron­tier of brain-machine interfaces

Final­ly, a quick cog­ni­tive exer­cise. Giv­en the uni­ver­sal beau­ty of math, you don’t need to speak Span­ish to try this quick teas­er: Brain teasers en español: ¿cuál es el número que fal­ta en el cuar­to triángulo?

Wish­ing you a hap­py and healthy summer,

The Sharp­Brains Team

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Education & Lifelong Learning, SharpBrains Monthly eNewsletter, Technology & Innovation Tagged With: aducanumab, Aduhelm, Alzheimers-disease, anti-amyloid drug, Biogen, Brain Teasers, brain-teaser, cognitive decline, cognitive-exercise, cognitive-health, dementia, digital mental health, lifelong-brain-health, Medicare, neurodegeneration, neurotechnologies, Neurotechnology, Pear Therapeutics, retirement

On building better brains at any age, treating Depression vs. Dementia, emerging neurotechnologies, psychedelics, and more

May 28, 2021 by SharpBrains

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing eleven new research find­ings and inno­v­a­tive resources for life­long cog­ni­tive and brain health.

#1. Debate: Are depres­sion and demen­tia two sides of the same coin? And, if they are, how to best approach treatment?

#2. Either way, the ear­li­er the bet­ter, but it’s nev­er too late: New book out­lines the five lifestyle pil­lars to “build a bet­ter brain at any age”

#3. “If I were a car­di­ol­o­gist eval­u­at­ing a patient’s chest pain, for instance, I would speak with the patient, but then I would lis­ten to their heart and mea­sure their pulse and blood pres­sure. I might order an elec­tro­car­dio­gram or a car­diac stress test, tools that weren’t avail­able a cen­tu­ry ago. Because I’m a psy­chi­a­trist, how­ev­er, I eval­u­ate patients in pre­cise­ly the same way that my pre­de­ces­sors did in 1920…” Read­ing Our Minds: New book issues strong call to action to mod­ern­ize psychiatry

#4. Very time­ly effort by Well­come in the UK: Com­pre­hen­sive research review iden­ti­fies most promis­ing inter­ven­tions to boost work­place men­tal health

#5. “As we enter the sec­ond year of the pan­dem­ic, so many peo­ple are strug­gling and seek­ing men­tal health sup­port. Wysa is an exam­ple of how tech­nol­o­gy is help­ing mil­lions of peo­ple access every­day men­tal health sup­port and self-care tools with­out being gat­ed by a clin­i­cal diag­no­sis.” — Dr. Pankaj Jeth­wani, Exec­u­tive Vice Pres­i­dent at W Health Ven­tures. Arti­fi­cial Intel­li­gence (AI)-enabled chat­bot Wysa rais­es $5.5M to broad­en access to men­tal health support

#6. Study: Social media and gen­er­al tech engage­ment not found to “fry” teenagers’ brains

#7. Akili Inter­ac­tive Labs rais­es $160M in equi­ty and debt to trans­form cog­ni­tive health­care via pre­scrip­tion videogame treat­ments. A nice way to cel­e­brate Akil­i’s 10th anniver­sary … they are tar­get­ing ADHD first (now kids, lat­er teens and adults), to be fol­lowed by treat­ments for a range of cog­ni­tive dis­or­ders relat­ed to depres­sion, Mul­ti­ple Scle­ro­sis, Autism, “Covid-Fog” and more.

#8. Study: High­er men­tal well­be­ing (in 2016) seen to low­er health­care costs (in 2017). We still have time to invest in pub­lic men­tal well­be­ing in 2021.

#9. Teladoc Health, hav­ing acquired Livon­go and myS­trength, launch­es inte­grat­ed men­tal health ser­vice for the work­place. “The announce­ment comes as more than half of peo­ple with men­tal health con­cerns report that they do not know where to start when get­ting care, high­light­ing the impor­tance of the dig­i­tal front door myS­trength Com­plete will pro­vide…” This is indeed a very com­mon pain point accord­ing to our own research, so good to see the quite com­pre­hen­sive & per­son­al­ized approach.

#10. Cumu­lus Neu­ro­science rais­es $8.3M to devel­op EEG-based wire­less ‘Fit­bit for the brain’ — Fas­ci­nat­ing to see the major role of the Demen­tia Dis­cov­ery Fund, in a bid to accel­er­ate clin­i­cal tri­als and poten­tial therapies.

#11. Last but not least, a very promis­ing clin­i­cal appli­ca­tion of psy­che­delics: Study finds MDMA-assist­ed ther­a­py to be safe and high­ly effec­tive to treat severe PTSD. “The Nature authors spec­u­late that MDMA-assist­ed ses­sions pro­duce a “win­dow of tol­er­ance,” in which patients are able to revis­it trau­mat­ic mem­o­ries, with less shame and anger, and with­out being over­whelmed by PTSD symptoms.”

Wish­ing you a healthy Memo­r­i­al Week­end and month of June,

The Sharp­Brains Team

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Brain/ Mental Health, Education & Lifelong Learning, Technology & Innovation Tagged With: brain health, cognitive, cognitive healthcare, cognitive--disorders, cognitive-health, Cumulus Neuroscience, dementia, depression, mental health, neurotechnologies, psychedelics, psychiatry, Teladoc Health, videogame, workplace

On centenarians, memory, Mars, tDCS, ADHD, digital health, beautiful brains, and more

April 30, 2021 by SharpBrains

Hen­drik­je van Andel Schip­per (1890–2005)

Wel­come to a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing ten time­ly resources and research find­ings for life­long brain and men­tal fitness.

#1. Let’s start with a fas­ci­nat­ing sto­ry and study 🙂

Study with 330 cen­te­nar­i­ans finds that cog­ni­tive decline is not inevitable … (Henne Hol­stege, PhD, assis­tant pro­fes­sor at Ams­ter­dam Uni­ver­si­ty Med­ical Cen­ter) said her inter­est in research­ing aging and cog­ni­tive health was inspired by the “fas­ci­nat­ing” sto­ry of Hen­drik­je van Andel Schip­per, who died at age 115 in 2005 “com­plete­ly cog­ni­tive­ly healthy.”

#2. Neu­ro­sci­en­tist Lisa Gen­o­va, author of the beau­ti­ful nov­el Still Alice, releas­es non-fic­tion book on Mem­o­ry: “It is sober­ing to real­ize that three out of four pris­on­ers who are lat­er exon­er­at­ed through DNA evi­dence were ini­tial­ly con­vict­ed on the basis of eye­wit­ness tes­ti­mo­ny. “You can be 100 per­cent con­fi­dent in your vivid mem­o­ry,” Gen­o­va writes, “and still be 100 per­cent wrong” … Gen­o­va assures her read­ers that only two per cent of Alzheimer’s cas­es are of the strict­ly inher­it­ed, ear­ly-onset kind. For most of us, our chances of devel­op­ing the dis­ease are high­ly amenable to interventions…”

#3. Time­ly tips for the week­end: Shape your envi­ron­ment, shape your mind

  • Sur­round your­self with nature
  • Cre­ate oppor­tu­ni­ties for awe
  • Clear the clutter

#4. “For a mis­sion to suc­ceed, high men­tal and cog­ni­tive func­tion would be absolute­ly crit­i­cal; astro­nauts would be called on to per­form demand­ing tasks in a demand­ing envi­ron­ment. Los­ing 20 IQ points halfway to Mars is not an option … Stress—an emo­tion­al or men­tal state result­ing from tense or over­whelm­ing circumstances—and the body’s response to it, which involves mul­ti­ple sys­tems, from metab­o­lism to mus­cles to memory—may be the chief chal­lenge that astro­nauts face.” Next in NASA’s path to Mars: Over­com­ing astro­nauts’ cog­ni­tive and men­tal health challenges

#5. Study: Depres­sion affects visu­al per­cep­tion … mak­ing it more accu­rate (based on a cool opti­cal illusion)

#6. It’s good to have more tools in the neu­ro toolkit…assuming we use them wise­ly: Emerg­ing appli­ca­tions of tran­scra­nial Direct Cur­rent Stim­u­la­tion (tDCS): e‑sports skills train­ing, cog­ni­tive enhance­ment in old­er adults

#7. Does ADHD treat­ment enable long-term aca­d­e­m­ic suc­cess? (Yes, espe­cial­ly when phar­ma­co­log­i­cal and non-phar­ma treat­ments are combined)

#8. Men­tal Health in the Dig­i­tal Age: From dig­i­tal ther­a­peu­tics to per­son­al­ized men­tal health solu­tions: Pear Ther­a­peu­tics expands plat­form via part­ner­ships with Empat­i­ca, etec­tRx, Key­Wise, and Winterlight

#9. The award was won last year by Indi­an vil­lage teacher Ran­jitsinh Disale; who will be next? Final day to nom­i­nate teach­ers for the $1M Glob­al Teacher Prize 2021

#10. And last, but cer­tain­ly not least, let’s wel­come Men­tal Health Month (May) by appre­ci­at­ing our beau­ti­ful brains

Wish­ing you a men­tal­ly healthy and cog­ni­tive­ly stim­u­lat­ing month of May,

The Sharp­Brains Team

Share this:

  • Tweet
  • Email
  • Print
  • More
  • Share on Tumblr
  • Pock­et

Filed Under: Attention & ADD/ADHD, Brain/ Mental Health, Education & Lifelong Learning, Technology & Innovation Tagged With: adhd, ADHD-Treatment, aging, Alzheimer’s, astronauts, beautiful brains, brain health, centenarians, cognitive decline, cognitive-function, cognitive-health, depression, digital health, digital therapeutics, IQ, MaRS, memory, Pear Therapeutics, Stress, tDCS, Transcranial-direct-current-stimulation

Next Page »

Primary Sidebar

Top Articles on Brain Health and Neuroplasticity

  1. Can you grow your hippocampus? Yes. Here’s how, and why it matters
  2. How learning changes your brain
  3. To harness neuroplasticity, start with enthusiasm
  4. Three ways to protect your mental health during –and after– COVID-19
  5. Why you turn down the radio when you're lost
  6. Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging
  7. Ten neu­rotech­nolo­gies about to trans­form brain enhance­ment & health
  8. Five reasons the future of brain enhancement is digital, pervasive and (hopefully) bright
  9. What Educators and Parents Should Know About Neuroplasticity and Dance
  10. The Ten Habits of Highly Effective Brains
  11. Six tips to build resilience and prevent brain-damaging stress
  12. Can brain training work? Yes, if it meets these 5 conditions
  13. What are cognitive abilities and how to boost them?
  14. Eight Tips To Remember What You Read
  15. Twenty Must-Know Facts to Harness Neuroplasticity and Improve Brain Health

Top 10 Brain Teasers and Illusions

  1. You think you know the colors? Try the Stroop Test
  2. Check out this brief attention experiment
  3. Test your stress level
  4. Guess: Are there more brain connections or leaves in the Amazon?
  5. Quick brain teasers to flex two key men­tal mus­cles
  6. Count the Fs in this sentence
  7. Can you iden­tify Apple’s logo?
  8. Ten classic optical illu­sions to trick your mind
  9. What do you see?
  10. Fun Mental Rotation challenge
  • Check our Top 25 Brain Teasers, Games and Illusions

Join 12,517 readers exploring, at no cost, the latest in neuroplasticity and brain health.

By subscribing you agree to receive our free, monthly eNewsletter. We don't rent or sell emails collected, and you may unsubscribe at any time.

IMPORTANT: Please check your inbox or spam folder in a couple minutes and confirm your subscription.

Get In Touch!

Contact Us

660 4th Street, Suite 205,
San Francisco, CA 94107 USA

About Us

SharpBrains is an independent market research firm tracking health and performance applications of brain science. We prepare general and tailored market reports, publish consumer guides, produce an annual global and virtual conference, and provide strategic advisory services.

© 2023 SharpBrains. All Rights Reserved - Privacy Policy